-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Tango Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2024.
- Tango Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$29.6M, a 27.1% decline year-over-year.
- Tango Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$132M, a 16.2% decline year-over-year.
- Tango Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$114M, a 2.79% decline from 2022.
- Tango Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$111M, a 90.9% decline from 2021.
- Tango Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$58.2M, a 11.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)